Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria

Blood

Volumn 98, Issue 2, 2001, Pages 442-449

  Holt, Dewi S ^a,b   Botto, Marina ^a,b   Bygrave, Anne E ^a,b   Melanie Hanna, S ^a,b   Walport, Mark J ^a,b   Paul Morgan, B ^a,b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACID; ANTIBODY; COMPLEMENT; COMPLEMENT MEMBRANE ATTACK COMPLEX; HEMOGLOBIN; SNAKE VENOM;

ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD59 GENE; CELL PROTECTION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; ERYTHROCYTE; ERYTHROCYTE LIFESPAN; GENE; GENE DELETION; GENE TARGETING; HEALTH; HEMOGLOBIN DETERMINATION; HEMOGLOBINURIA; IN VITRO STUDY; INTRAVASCULAR HEMOLYSIS; LYSIS; MOUSE; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PLASMA; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RETICULOCYTE COUNT; SERUM; STAINING; STEM CELL; THROMBOSIS; URINE;

EID: 0035880233     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.2.442     Document Type: Article

References (39)

1. Morgan BP, Harris CL. Complement regulatory proteins. London, United Kingdom: Academic Press; 1999.
2. Meri S, Morgan BP, Davies A, et al. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology. 1990;71:1-9.
3. Tsujimura A, Shida K, Kitamura M, et al. Molecular cloning of a murine homologue of membrane cofactor protein (CD46): preferential expression in testicular germ cells. Biochem J. 1998;330:163-168.
4. Mead R, Hinchliffe SJ, Morgan BP. Molecular cloning, expression and characterization of the rat analogue of human membrane cofactor protein (MCP/CD46). Immunology. 1999;98:137-143.
5. Kim YU, Kinoshita T, Molina H, et al. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J Exp Med. 1995;181:151-159.
6. Rosse WF. Paroxysmal nocturnal hemoglobinuria. Curr Top Microbiol Immunol. 1992;178:163-173.
7. Telen MJ, Green AM. The Inab phenotype: characterization of the membrane protein and complement regulatory defect. Blood. 1989;74:437-441.
8. Merry AH, Rawlinson VI, Uchikawa M, Daha MR, Sim RB. Studies on the sensitivity to complement-mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (decay accelerating factor). Br J Haematol. 1989;73:248-253.
9. Reid ME, Mallinson G, Sim RB, et al. Biochemical studies on red blood cells from a patient with the Inab phenotype (decay-accelerating factor deficiency). Blood. 1991;78:3291-3297.
10. Lublin DM, Mallinson G, Poole J, et al. Molecular basis of reduced or absent expression of decay-accelerating factor in Cromer blood group phenotypes. Blood. 1994;84:1276-1282.
11. Okada N, Harada R, Taguchi R, Okada H. Complete deficiency of 20 KDa homologous restriction factor (HRF20) and restoration with purified HRF20. Biochem Biophys Res Comm. 1989;164:468-473.
12. Yamashina M, Ueda E, Kinoshita T, et al. Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1990;323:1184-1189.
13. Matsuo S, Ichida S, Takizawa H, et al. In vivo effects of monoclonal antibodies that functionally inhibit complement regulatory proteins in rats. J Exp Med. 1994;180:1619-1627.
14. Spicer AP, Seldin MF, Gendler SJ. Molecular cloning and chromosomal localization of the mouse decay-accelerating factor genes: duplicated genes encode glycosylphosphatidylinositol-anchored and transmembrane forms. J Immunol. 1995;155:3079-3091.
15. Sun XC, Funk D, Deng C, Sahu A, Lambris JD, Song WC. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proc Natl Acad Sci U S A. 1999;96:628-633.
16. Xu C, Mao D, Holers VM, Palanca B, Cheng AM, Molina H. A critical role for murine complement regulator Crry in fetomaternal tolerance. Science. 2000;287:498-501.
17. Powell MB, Marchbank KJ, Rushmere NK, van den Berg CW, Morgan BP. Molecular cloning, chromosomal localization, expression, and functional characterization of the mouse analogue of human CD59. J Immunol. 1997;158:1692-1702.
18. Holt DS, Powell MB, Rushmere NK, Morgan BP. Genomic structure and chromosome location of the gene encoding mouse CD59. Cytogenet Cell Genet. 2000;89:264-267.
19. Harris CL, Rushmere NK, Morgan BP. Molecular and functional analysis of mouse decay accelerating factor (CD55). Biochem J. 1999;341:821-829.
20. Spiller OB, Hanna SM, Morgan BP. Tissue distribution of the rat analogue of decay-accelerating factor. Immunology. 1999;97:374-384.
21. Harboe MA. A method for determination of hemoglobin in plasma by near-ultraviolet spectrophotometry. Scand J Clin Lab Invest. 1959;11:66-70.
22. Fairbanks VF, Ziesmer SC, O'Brien PC. Methods for measuring plasma hemoglobin in micromolar concentration compared. Clin Chem. 1992;38:132-140.
23. Tremml G, Dominguez C, Rosti V, et al. Increased sensitivity to complement and a decreased red blood cell life span in mice mosaic for a nonfunctional Piga gene. Blood. 1999;94:2945-2954.
24. Nielsen PJ, Lorenz B, Muller AM, et al. Altered erythrocytes and a block in B cell development in CD24/HSA-deficient mice, Blood. 1997;89:1058-1067.
25. Morgan BP. Measurement of complement hemolytic activity, generation of complement-depleted sera and production of hemolytic intermediates. Meth Mol Biol. 2000;150:61-72.
26. Ham TH. Chronic haemolytic anaemia with paroxysmal nocturnal haemoglobinuria: a study of the mechanism of haemolysis in relation to acid-base equilibrium. N Engl J Med. 1937;217:915-917.
27. Nomura A, Nishikawa K, Yuzawa Y, et at. Tubulointerstitial injury induced in rats by a monoclonal antibody that inhibits function of a membrane inhibitor of complement. J Clin Invest. 1995;96:2348-2356.
28. Nishikawa K, Matsuo S, Okada N, Morgan BP, Okada H. Local inflammation caused by a monoclonal antibody that blocks the function of the rat membrane inhibitor of C3 convertase. J Immunol. 1996;156:1182-1188.
29. Mizuno M, Nishikawa K, Goodfellow RM, Piddlesden SJ, Morgan BP, Matsuo S. The effects of functional suppression of a membrane-bound complement regulatory protein, CD59, in the synovial tissue in rats. Arthritis Rheum. 1997;40:527-533.
30. Matsuo S, Nishikage H, Yoshida F, Nomura A, Piddlesden SJ, Morgan BP. Role of CD59 in experimental glomerulonephritis in rats. Kidney Int. 1994;46:191-200.
31. Parker CJ. Molecular basis of paroxysmal nocturnal hemoglobinuria. Stem Cells. 1996;14:396-411.
32. Motoyama N, Okada N, Yamashina M, Okada H. Paroxysmal nocturnal hemoglobinuria due to hereditary nucleotide deletion in the HRF20 (CD59) gene. Eur J Immunol. 1992;22:2669-2673.
33. Fishelson Z, Horstmann RD, Muller-Eberhard HJ. Regulation of the alternative pathway of complement by pH. J Immunol. 1987;138:3392-3395.
34. Hammer CH, Hansch G, Gresham HD, Shin ML. Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a. J Immunol. 1983;131:892-898.
35. Hansch G, Hammer C, Jiji R, Rother U, Shin M. Lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by acid activated serum. Immunobiology. 1983;164:118-126.
36. Murakami Y, Kinoshita T, Maeda Y, Nakano T, Kosaka H, Takeda J. Different roles of glycosylphosphatidylinositol in various hematopoietic cells as revealed by a mouse model of paroxysmal nocturnal hemoglobinuria. Blood. 1999;94:2963-2970.
37. Dacie J. Paroxysmal nocturnal haemoglobinuria I: history, clinical, haematological and pathological findings. In: The Haemolytic Anaemias. Vol. 5. London: Churchill Livingstone; 1999:139-196.
38. Cochrane CG, Koffler D. Immune complex disease in experimental animals and man. Adv Immunol. 1973;16:185-264.
39. Qian YM, Qin X, Miwa T, Sun X, Halperin JA, Song WC. Identification and functional characterization of a new gene encoding the mouse terminal complement inhibitor CD59. J Immunol. 2000;165:2528-2534.